Supporting the development of an inexpensive, rapid, near-patient test panel of coagulation markers
Baebies was recently awarded a Phase IIB SBIR grant from the National Institutes of Health (NIH) for a project to develop a coagulation test panel utilizing very small volumes of blood with a rapid turn-around time. Newborns and young children undergoing cardiac surgery are at a significantly increased risk for a major thrombosis event, and comprehensive hypercoagulability testing is indicated in children who have suffered a major thrombotic or thromboembolic event, or who have a family history of thrombosis. Currently available coagulation tests are time-consuming and must be ordered individually, which increases the cumulative volume of blood sample required.
This funding enables continued development of a test panel of coagulation analytes on our near-patient digital microfluidic system combining immunoassays, molecular assays, and enzyme activity assays utilizing a small volume of blood sample. Our development is purposefully aimed at a product that generates rapid results from small sample volumes to provide a comprehensive assessment of hypercoagulability risk and address a critical unmet need in pediatric coagulation management.
Our team is strengthened by a long-standing collaboration with a top-rated pediatric cardiac surgeon, Dr. Sitaram Emani, at Boston Children’s Hospital.
National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) is the funding agency for this grant. Phase IIB awards provide additional funding to help bridge the gap between R&D and commercialization. Combined with the successfully completed Phase I and II project periods, this project has received a total of $3M in NIH grant funding.
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This product is not available for sale or use in any territory.
Read more in Baebies SBIR Success Story